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Abstract
The liver is the primary site of metastasis for gastrointestinal cancers and is a location highly 
susceptible to the establishment of metastasis in numerous other primary cancers, including breast, 
lung, and pancreatic cancers. The current standard of care typically consists of primary tumor 
resection and systemic administration of potent but toxic chemotherapeutics, yielding a minimal 
improvement in the median survival rate. CXCL12, a chemokine, is a key factor for activating the 
migration/survival pathways of CXCR4+ cancer cells and for recruiting immunosuppressive cells 
to areas of inflammation. Therefore, reducing CXCL12 concentrations within the liver has the 
potential to decrease tumor and immunosuppressive cell activation/migration within the liver. 
However, because of off-target toxicities associated with systemic administration of anti-CXCL12 
therapies, transient and liver-specific expression of a CXCL12 trap is necessary. To address this 
challenge, we developed a lipid calcium phosphate nanoparticle optimized for delivering plasmid 
DNA, encoding an engineered CXCL12 protein trap, to the nucleus of liver hepatocytes. This 
pCXCL12-trap formulation yielded transient (4 days) liver-specific expression, which greatly 
decreased the occurrence of liver metastasis in two aggressive liver metastasis models, including 
colorectal [CT-26(FL3)] and breast (4T1) cancers. Subsequent studies in an aggressive human 
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colorectal liver metastasis model (HT-29) decreased the establishment of liver metastasis more 
effectively than did systemic administration of the CXCL12 protein trap and to a level comparable 
to a high-dose regimen of a potent CXCR4 antagonist (AMD3100).
INTRODUCTION
Colorectal cancer (CRC) is the third most prevalent cancer diagnosed worldwide and the 
third leading cause of cancer deaths. In the United States alone, about 143,460 patients were 
diagnosed, resulting in more than 51,690 deaths in 2012 (1). However, the cause of death is 
rarely due to the primary colon cancer burden itself, because local resection of cancerous 
colon is quite efficient. Unfortunately, the establishment of liver metastasis is the leading 
cause of death (1). At early stages of CRC detection, before liver metastases form, the 5-year 
survival rate is about 90%. Regrettably, this rate drops to less than 12% once liver metastasis 
has been established. By the time of diagnosis, 20% of patients have developed liver 
metastasis, and 60 to 70% of patients develop metastatic lesions in the liver by the time of 
death (2). Currently, the approved treatment for liver metastasis consists of liver resection 
and/or a combination of 5-fluorouracil with oxaliplatin or irinotecan with or without 
capecitabine. These treatments yield an overall response rate of 20 to 30% or 40 to 50%, 
depending on regimen, and a median overall survival of 12 to 20 months (3). Although these 
treatments are currently the standard of care and yield improved efficacy over other 
traditional treatments, the off-target toxicities along with a median survival of 12 to 20 
months presents a less than desirable outcome. Therefore, a key strategy to improve the 
survival rate and quality of life for patients with CRC and other cancers undergoing 
treatment is to reduce off-target toxicities. This can be achieved through tissue-specific 
targeting of central factors that directly activate liver metastasis and subsequently promote 
the establishment of an immunosuppressive tumor microenvironment.
The relationship between the chemokine receptor CXCR4 expressed on cancer cells and its 
chemokine ligand, stromal derived factor-1 (CXCL12/SDF-1), secreted by the hepatic 
stellate cells (HSCs), plays a vital role in CRC and numerous other cancer liver metastasis 
(4). These HSCs are resident perisinusoidal cells that have been shown to produce high 
amounts of endogenous CXCL12 for recruitment of immunosuppressive lymphocytes such 
as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) to areas of 
inflammation. In the presence of high amounts of CXCL12, CXCR4+ CRC cells migrate and 
invade along the CXCL12 concentration gradient. In addition, CXCR4 is expressed in a 
maintenance capacity in CRC progenitor cells to maintain stem-like characteristics (5, 6). 
Further analyses of human CRC biopsies have found that a higher rate of liver metastasis 
correlates with high expression of CXCR4 (4, 7). Therefore, we hypothesized that disrupting 
this CXCL12 gradient in the liver may effectively decrease the occurrence and progression 
of colorectal and numerous other CXCR4+ cancers in the liver while drastically reducing the 
recruitment of immunosuppressive cells.
Treatment of mice with AMD3100 (plerixafor), a small-molecule CXCR4 antagonist, has 
demonstrated the therapeutic potential of disrupting the CXCL12/CXCR4 axis, resulting in 
the decreased occurrence of liver metastasis (8). Subsequently, many CXCR4 antagonists 
Goodwin et al. Page 2
Sci Transl Med. Author manuscript; available in PMC 2017 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
have been developed (9). However, the endogenous role of CXCL12 and CXCR4 in the 
immune system is vital. These treatments, which include small-molecule and protein 
therapies, come with systemic off-target toxicity concerns. Furthermore, to our knowledge, 
no therapy targeted to CXCL12 has been developed and reported to reduce the occurrence of 
colorectal liver metastasis. Therefore, we hypothesized that an anticancer strategy centered 
on the liver-specific delivery of a gene encoding a small antibody-like protein to entrap 
CXCL12, and thereby alter the liver microenvironment, could be used to halt metastasis to 
the liver. Delivery of such genes can achieve reduced concentrations of CXCL12 or similar 
factors, priming the liver to directly reduce activation of the migration/invasion/survival/
proliferation pathways in CXCR4+ CRC cells. Furthermore, this strategy has the potential to 
decrease the recruitment of CXCR4+ immunosuppressive cell types. Therefore, targeting 
protein factors, such as CXCL12, in the micro-environment of healthy tissue brings about an 
anticancer paradigm in which the metastatic lesions are not targeted directly. Instead, the 
metastasis-prone environment is primed to be unsuitable for the metastasis to form or 
progress, ultimately decreasing the establishment and growth of metastatic lesions.
The development and use of a reliable syngeneic orthotopic colorectal liver metastasis 
animal model enabled investigation into the role of CXCL12 in promoting liver metastasis. 
This model, first reported by Zhang et al., involves inoculation of 2.0 × 106 CT-26(FL3) 
cells into the cecum wall to yield a high occurrence of liver metastasis (~90%) within 4 
weeks (10). Subsequent establishment of a CT-26(FL3) cell line stably expressing red 
fluorescent protein (RFP)/luciferase (Luc) marker genes allowed the use of luciferase 
bioluminescent analysis to determine in vivo liver tumor burden. Through the use of this 
model, as well as the establishment of liver metastasis via hemi-splenic inoculation of 
human colorectal (HT-29) or mouse breast cancer (4T1) cell lines, we could investigate our 
therapy’s ability to prime the liver microenvironment and the tumor/immune cell profile. 
The use of syngeneic models allowed us to investigate the immune profile and the role of 
cytotoxic T lymphocytes (CTLs) in reducing the progression and establishment of liver 
metastasis. Furthermore, investigation of liver metastasis in an immunodeficient athymic 
mouse model provides insight into whether the direct disruption of the CXCR4/CXCL12 
axis on the cancer cells’ surface is a therapeutic pathway for reducing the establishment of 
liver metastasis. These mouse models produce a reliable platform to examine whether the 
proposed strategy can be used to demonstrate in vivo anticancer efficacy on numerous 
CXCR4+ derived colorectal cell lines, such as CT-26(FL3) and HT-29, as well as other 
cancers such as breast cancer (4T1) (fig. S1). We hypothesized that the targeted (liver-
specific) delivery and transient expression of the engineered CXCL12 trap (Trap; 28.6 kDa) 
via a lipid calcium phosphate (LCP) nonviral vector can direct the liver to resist infiltrating 
CXCR4+ metastatic cells as well as inhibit the establishment of an immunosuppressive 
tumor microenvironment, allowing for enhanced cancer-specific CD8+ T cell killing.
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RESULTS
Reduction of migration/invasion of CXCL12-stimulated CT-26(FL3) cells by engineered 
CXCL12 trap
The CXCL12 trap gene was designed on the basis of known anti-CXCL12 antibody 
sequences. This was accomplished by fusing a VH and a VL domain through a protease-
resistant flexible linker. Subsequently, a strong signaling peptide from human serum albumin 
preproprotein was incorporated at the N terminus to efficiently facilitate the secretion from 
liver hepatocytes after expression (11), whereas E and His(6×) tags were introduced at the C 
terminus to facilitate protein purification and in vivo expression analysis. The coding 
sequence of the CXCL12 trap was cloned into the expression vector pCDNA3.1, driven by a 
cytomegalovirus promoter. The recombinant CXCL12 trap was expressed in and purified 
from 293 T cells. The target-binding features, such as the binding affinity and specificity for 
CXCL12 and other chemokines, were measured through biolayer interferometry (BLI) (Fig. 
1A). The engineered CXCL12 trap was found to have a dissociation constant (Kd) of 4.1 nM 
for CXCL12 (Fig. 1A). It has been reported that treatment of CT-26(FL3) cells with the 
recombinant CXCL12 chemokine yields up-regulation of the migration/invasion pathways 
(4, 5). Therefore, we investigated the ability of our CXCL12 trap (Trap) and a commercially 
available CXCL12 antibody to suppress the migration and invasion of CT-26(FL3) cells 
down a concentration gradient of CXCL12 (Fig. 1, B and C). Although the in vitro half-
maximal inhibition (ND50) is not a direct indicator of affinity of the CXCL12 trap or 
CXCL12 antibody to the CXCL12, these in vitro experiments demonstrated the Trap’s 
ability to decrease the migration and invasion of CT-26(FL3) (RFP/Luc) cells down a 
concentration gradient of CXCL12 (10 nM). Our results indicate complete suppression of 
the migration and invasion at a Trap concentration of 240 nM (Fig. 1, B and C). The 
CXCL12 trap produced ND50 against biologically active CXCL12 (10 nM) in vitro at a 
concentration of about 120 nM (Fig. 1, B and C). Commercially available CXCL12 antibody 
(ND50 of 12 to 24 nM) was used as a positive control (Fig. 1, B and C).
Formulation and characterization of galactose-LCP pDNA/mc-CR8C nanoparticles
Hu et al. (12) reported the formulation and delivery of the galactose-LCP with pDNA/mc-
CR8C cargo to the liver hepatocytes of mice. The core structure can be visualized under 
transmission electron microscopy (TEM) (fig. S2A). The 1,2-dioleoyl-sn-glycero-3-
phosphate (DOPA) monolayer surrounding the CaP core allows for the addition of the 
cationic outer leaflet lipids, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), helper 
lipid cholesterol, and galactose conjugated to 1,2-distearoyl-sn-glycero-3-
phosphatidylethanolamine-N-succinyl(polyethylene glycol)-2000 (GAL-DSPE-PEG2000) to 
assist in reticuloendothelial system, RES, evasion and hepatocyte uptake, producing the final 
LCP particles (40 to 60 nm in diameter, shown in fig. S2, B and C). The hydrodynamic 
diameter and the surface charge of the LCP particles were found via dynamic light scattering 
(DLS) zetasizer analysis to be about 45 nm and 10 mV, respectively (fig. S2C). The excess 
lipids not incorporated into the outer lipid layer of the LCP form liposomes with a diameter 
of about 350 nm. The LCP and liposome mixture result in a z average of 236 ± 32 nm (n = 
6). The solution was found to be stable in 10% fetal bovine serum at 37°C for at least 24 
hours in which no significant increase in the z average was observed (fig. S2D). The pDNA 
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encapsulation efficiency was found to be about 50 to 60%, which corresponds closely to the 
reported formulation by Hu et al. (12). Liver specificity, pharmaco-kinetics (PK), and organ 
distribution were determined through incorporation of 177Lu radioisotope along with the 
nuclear-localizing signal peptide/pDNA into the LCP core. The LCP particles 
containing 177Lu were injected through the tail vein into healthy BALB/c mice. The PK and 
organ distribution profile studies demonstrate that the galactose-LCP nanoparticles exhibit a 
two-phase distribution with T1/2a and T1/2b of 20 and 1054 min, respectively, as well as 
about 50% of the injected dose per gram tissue accumulating in the liver 16 hours after 
intravenous injection (fig. S3).
In vivo expression profile of pDNA (pGFP and pTrap) via LCP formulation
Hu et al. reported that most of the pDNA encapsulated in the highly PEGylated LCP vector 
was delivered and expressed in the hepa-tocytes. Furthermore, the decreased PEG density 
and the absence of a galactose-targeting ligand shifted the uptake preferentially into the 
Kupffer cells, decreasing expression of the pDNA (12). Therefore, to ensure hepatocyte 
uptake and expression, we used a high PEG density (30% mol input) and galactose-targeting 
ligand (5% mol input) throughout the formulation of the pDNA LCP vector. We investigated 
the preferential expression of the green fluorescent protein plasmid (pGFP) and CXCL12 
trap plasmid (pTrap) in the liver versus other organs/serum to ensure preferential liver-
specific expression of the delivered pDNA. We delivered pGFP LCP to observe GFP 
expression in the liver (Fig. 2A). Through fluorescent microscopy analysis of organ sections 
on days 2, 4, and 8 after the final pGFP LCP injection, we could demonstrate transient liver-
specific expression lasting up to 4 days. No GFP signal was found in any other major organ 
sections. Furthermore, expression of GFP was found to be predominately in the hepatocyte 
population within the liver (fig. S4). Subsequently, expression of the CXCL12 trap was 
assessed by enzyme-linked immunosorbent assay (ELISA) and Western blot analysis using 
the His(6×)-tag engineered at the C terminus of the CXCL12 trap (Fig. 2, B and C). Mice 
were treated with increasing doses of pTrap LCP (0.1, 0.5, and 1.0 mg/kg). Through ELISA 
and Western blot analysis, we observed a dose-dependent increase in liver expression 24 
hours after intravenous injection, with no significant expression found in other major organs 
or serum (Fig. 2B). Further, Western blot studies demonstrated the transient expression time 
profile in which pTrap LCP (10 mg of pDNA; 0.5 mg/kg every other day × 3) was 
administered intravenously followed by collection of the livers on days 1, 2, 4, and 8 after 
the final LCP administration (Fig. 2C). The results indicate that the pDNA LCP vector 
elicits transient liver-specific expression of the CXCL12 trap, similar to the GFP expression 
profile, yielding expression for at least 4 days after the final injection (10 mg of pDNA; 0.5 
mg/kg every other day × 3) (Fig. 2, A to C). These results demonstrate that the galactose-
LCP vector allows for preferential transient expression in the hepatocytes, with minimal 
expression in other organs or serum (Fig. 2).
Modifying CXCL12 expression and immune cell populations in the liver of CRC mice
Colorectal liver metastasis was established through injection of 2 × 106 CT-26(FL3) cells 
into the mouse cecum wall. Zhang et al. reported that initial micrometastatic lesions form 14 
days after inoculation of cells. The formation of large metastatic lesions and euthanasia of 
the mice because of large primary tumors in the intestine was reported 4 weeks after 
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inoculation (10), which corresponded closely to our observations. Therefore, prophylactic 
liver metastasis treatment with pTrap LCP (10 mg of pDNA; 0.5 mg/kg every other day × 3) 
was initiated 10 days after inoculation, before the formation of measurable liver metastases. 
We first assessed whether the delivery of pTrap LCP would decrease CXCL12 
concentrations as well as inflammation as a result of the reduced presence of metastatic 
lesions, as shown in Fig. 3A. The expression of endogenous CXCL12 in the liver of CRC-
bearing BALB/c mice was investigated in liver sections through immunofluorescence 
staining for CXCL12. The amount of CXCL12 found in the livers of CRC mice was 
compared to sections obtained from normal (healthy) mice without CRC to better 
understand the shifts in the endogenous expression of CXCL12 in the CRC liver metastasis 
model. The livers were assessed on day 24 (10 days after the final injection) by staining for 
CXCL12 (red, Fig. 3A). We studied five groups, four of which contained CRC, as follows: 
healthy (no CRC), untreated [treated with phosphate-buffered saline (PBS)], pGFP LCP 
control (10 mg every other day × 3), pTrap LCP (10 mg, single injection), and pTrap LCP 
(10 mg every other day × 3). Figure 3A shows that the untreated and pGFP-treated CRC 
mice had comparable expression of CXCL12 and that it was five- to sixfold higher than in 
the healthy livers from mice without CRC. The increased CXCL12 is believed to be a result 
of inflammation induced by the presence of the metastatic lesions. However, pTrap LCP (10 
mg and 10 mg every other day × 3) treatment resulted in 2.5- and 5-fold decreases in 
fluorescence intensity, respectively, compared to the untreated animals, reaching baseline 
expression of CXCL12 in the group that received three doses of the Trap (Fig. 3A). 
Endogenous expression of CXCL12 in major organs of healthy mice (no CRC) is shown in 
fig. S5. Having observed the reduction in liver CXCL12 after treatment with pTrap LCP, we 
further stained the tissue sections to determine the effect of treatment on the liver immune 
cell populations, including MDSCs, Tregs, and CD8+ T cells (Fig. 3B). These immune cells 
have substantial CXCR4 expression and therefore are recruited by endogenous CXCL12 
(13). Four groups were studied, including sections from the livers of healthy mice (no CRC), 
untreated livers containing metastatic lesions (tumor), untreated livers containing increased 
collagen (stroma), as well as those treated with pTrap LCP (10 mg every other day × 3), in 
which metastatic lesions were not observed. The staining indicated that there is a drastic 
increase in the MDSC, Treg, and CD8+ T cell population in the untreated (tumor and stroma) 
groups compared to the healthy (no CRC) group. The pTrap LCP–treated group had low 
numbers of MDSCs and Tregs, similar to the healthy livers (no CRC). However, an increase 
was observed in the CD8+ T cell population in the pTrap LCP group compared to the 
healthy (no CRC) group. It must be noted, however, that this amount of CD8+ T cells was 
still twofold lower than in the untreated groups, in which metastatic lesions and 
inflammation were present (Fig. 3B). This is consistent with the metastatic lesions’ ability to 
cause local inflammation, which results in increased CXCL12 and a subsequent influx of 
anti- and proinflammatory immune cells into the liver (Fig. 3B). Although the untreated 
CRC livers had the highest influx of CD8+ T cells, the large numbers of immunosuppressive 
MDSC and Treg populations are likely to neutralize the CD8+ T cells before they can 
mediate cancer-specific killing. However, after pTrap treatment, the moderate increase in the 
CD8+ T cell population in the presence of minimal immunosuppressive cells may allow for 
adequate surveillance and cancer-specific killing before the immunosuppressive metastatic 
lesion is formed.
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Therapeutic efficacy of pTrap LCP in an orthotopic syngeneic colorectal liver metastasis 
mouse model
We examined the effect of pTrap LCP on the incidence of liver metastasis in mice. Mice 
were inoculated with 2.0 × 106 CT-26(FL3) (RFP/Luc) cells orthotopically into the cecum 
wall. Three treatment groups were evaluated, including untreated (PBS), a vector/pDNA 
control (pGFP LCP), and pTrap LCP. Administration of treatment began on day 10 after 
inoculation. Intravenous tail vein injections [10 mg (0.5 mg/kg) of pDNA] were 
administered on days 10, 12, and 14. The total tumor burden was monitored by 
intraperitoneal administration of 200 ml of luciferin (10 mg/ml) followed by bio-
luminescent analysis 10 min after luciferin administration. The tumor burden was recorded 
weekly and used to sort mice into treatment groups before day 10. The tumor burden on day 
24 is shown in fig. S6. On day 24, mice were imaged and euthanized because of heavy 
primary tumor burden in the cecum. Livers and other organs were harvested and analyzed by 
bioluminescence imaging to determine metastatic tumor burden (Fig. 4, A and B). After 
bioluminescent analysis, livers were fixed, sectioned, and trichrome-stained for further 
morphological analysis (Fig. 4C). Mice treated with PBS or pGFP LCP developed large 
metastatic tumor lesions in the liver (Fig. 4, A and B), which caused prominent fibrotic 
tissue and cirrhosis (Fig. 4C). In contrast, mice treated with pTrap LCP (10 mg of pDNA) 
three times showed a 10-fold reduction in liver metastasis burden and about a 70 to 80% 
decrease in the incidence of liver metastasis formation (Fig. 4, A and B). The fibrotic area 
detected by microscopic analysis of the trichrome-stained liver sections was significantly 
less in specimens from pTrap LCP mice than in control specimens (P = 0.0001) (Fig. 4C). 
Although the rate of liver metastasis was reduced, the primary and distal tumor burden 
outside of the liver remained unchanged with this treatment (Fig. 4B).
Enhancement of antimetastasis efficacy of pTrap LCP therapy by cancer-specific T cells
The decreased MDSC and Treg populations in the liver after pTrap LCP treatment, along 
with the presence of CD8+ lymphocytes, implicate a shift from a protumor 
(immunosuppressive) to antitumor environment within the liver. Therefore, we examined the 
CTLs’ ability to decrease the establishment of metastasis in the liver after pTrap LCP 
therapy. To investigate the pTrap LCPs’ ability to enhance cancer-specific CD8+ T cell 
killing, we studied the anticancer efficacy of the pTrap LCP in mice with a depleted CD8+ T 
cell population. We followed a protocol similar to that reported by Harimoto et al. (14), in 
which ≥95% of the CD8+ T cell population was depleted after two intraperitoneal injections 
of 400 mg of anti-Lyt2.2 [2.43; rat immunoglobulin G2b (IgG2b)]. Mice were inoculated 
with CRC according to the orthotopic syngeneic model described earlier, followed by T cell 
depletion before treatment. In this series of experiments, the animals were divided into three 
treatment groups: untreated (PBS), pTrap LCP with anti-CD8 (anti-Lyt2.2), and pTrap LCP 
with an antibody isotype control (rat IgG2b isotype control). To maintain the depletion of 
the CD8+ T cell population, we administered an intraperitoneal injection of the anti-Lyt2.2 
or isotype control IgG (400 mg) on days 8 and 10. Treatment was initiated on day 10 after 
inoculation, with intravenous tail vein injection (10 mg of pDNA) on days 10, 12, and 14. 
Mice were euthanized because of heavy primary tumor burden in the cecum on day 21, and 
the liver tumor burden was determined through bioluminescence imaging (Fig. 5). All mice 
treated with the PBS developed large metastatic tumor lesions in the liver (Fig. 5). The T 
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cell– depleted mice treated with anti-Lyt2.2 followed by three doses of pTrap LCP (10 mg of 
pDNA) showed similar liver tumor burden to the untreated mice. In contrast, mice treated 
with the isotype control IgG2b antibody followed by pTrap LCP showed a fivefold reduction 
in liver metastasis burden and about an 80% decrease in the incidence of liver metastasis 
compared to untreated animals. These results show that the presence of CTLs, along with 
reduction in CXCL12, decreases the risk of establishing metastatic lesions in the liver.
Reduced metastatic burden and increased survival in breast cancer liver metastasis model
We examined the effect of pTrap LCP on the median survival and liver tumor burden in an 
aggressive mouse breast cancer liver metastasis model. The breast cancer liver metastasis 
model consists of the hemi-splenic implantation of a highly metastatic murine breast cancer 
cell line 4T1. These studies modeled the clinical standard of care, in which the primary 
tumor is resected and death usually results from the metastatic burden. BALB/c mice were 
inoculated with 1.0 × 106 (0.1 ml) of 4T1(GFP/Luc) cells into one-half of the spleen, which 
had been tied off and separated into two halves before the tumor inoculation. The hemi-
spleen that received the cells was resected 10 min after inoculation to decrease primary 
tumor growth. In this series of experiments, treatments began on the day of inoculation 
because of the rapid migration of cells to the liver, often within 5 min after inoculation (15). 
We studied four treatment groups for the breast cancer liver metastasis model: untreated 
(PBS), pGFP LCP with anti-CD8 [10 mg (0.5 mg/kg) of pDNA and 400 mg (20 mg/kg) of 
anti-Lyt2.2], pTrap LCP with anti-CD8 [10 mg (0.5 mg/kg) of pDNA and 400 mg (20 
mg/kg) of anti-Lyt2.2], and pTrap LCP with isotype IgG [10 mg (0.5 mg/kg) of pDNA and 
400 mg (20 mg/kg) of isotype IgG]. PBS, pGFP LCP, or pTrap LCP was administered 
intravenously via tail vein injections every other day starting on day 0 and ending on day 6. 
Administration of the anti-Lyt2.2 or isotype IgG control involved two intraperitoneal 
injections on days 0 and 2. Tumor progression was monitored by bioluminescence imaging 
(Fig. 6A). Mice were euthanized when one of the following conditions applied: drastic 
weight gain or loss greater than 10% within 1 week or clear signs of distress, such as 
dehydration, inactivity, or shortness of breath/weak breathing. Three mice from each group 
were euthanized 10 days after inoculation, their organs were collected and rinsed in PBS, 
and the livers were analyzed for tumor burden by flow cytometry analysis (Fig. 6B). Mice 
that did not receive pTrap LCP treatment developed large metastatic tumor lesions in the 
liver within the first week after inoculation (Fig. 6, A and B). In contrast, mice treated with 
pTrap LCP showed a reduction in liver metastasis burden and decrease in the incidence of 
liver metastasis formation, as well as an almost twofold increase in the median survival 
versus all other treatment groups (14 days versus 25 days) (Fig. 6C).
Reducing the establishment of liver metastasis by pTrap LCP, Trap protein, and CXCR4 
antagonist
We compared the efficacy of different therapeutic modalities [anti-CXCL12 trap protein, 
CXCR4 small-molecule antagonist (AMD3100), and the pTrap LCP] in reducing the 
establishment of liver metastasis using a human CRC cell line (HT-29) in immunodeficient 
athymic mice. The human CRC liver metastasis model was established according to the 
same hemi-splenic implantation procedure as above, using CRC cell line HT-29, which has 
high expression of CXCR4 (fig. S1). In this series of experiments, treatments again began on 
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the day of inoculation because of the rapid migration of cells to the liver within 5 min after 
inoculation (15). The five treatment groups studied for the CRC liver metastasis model were 
untreated (PBS), pGFP LCP [10 mg (0.5 mg/kg) of pDNA], pTrap LCP [10 mg (0.5 mg/kg) 
of pDNA], free CXCL12 trap protein [10 mg (0.5 mg/kg) of protein], and AMD3100 (100 
mg, 5.0 mg/kg). The treatments were administered intravenously by tail vein injection every 
other day, initiated on day 0, and terminated on day 16 (Fig. 7A). Mice were euthanized on 
day 36, their livers were collected and rinsed in PBS, and tumor nodules were resected from 
the livers and weighed (Fig. 7B). Mice that did not receive pTrap LCP or AMD3100 
treatment developed numerous metastatic tumor lesions in the liver (Fig. 7B). In contrast, 
mice treated with pTrap LCP or AMD3100 showed a reduction in liver metastasis burden 
and decreased incidence of liver metastasis formation compared to all other treatment 
groups.
Toxicity analysis of pTrap LCP and free CXCL12 trap protein
Administration of pTrap LCP (10 mg every other day × 3) did not cause any significant 
changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, or 
blood urea nitrogen (BUN), and there were no signs of toxicity in trichrome-stained 
histology sections of any organ 24 hours after the final intravenous tail vein injection (Fig. 8, 
A and B). Analysis of blood cell counts showed no signs of change compared to untreated 
mice (Fig. 8A). However, analysis of mouse serum and whole blood samples after systemic 
intravenous injection of 20 mg of engineered CXCL12 trap protein (every other day × 3) 
identified transient elevations of ALT and AST on day 7 after the final injection. In addition, 
the white blood cell counts drastically decreased between days 1 and 7, with a slight 
recovery of white blood cell counts by day 14 after the final injection (Fig. 8A). Histological 
analysis of trichrome-stained organ sections found no signs of toxicity for any of the 
treatment groups.
DISCUSSION
To prime the liver to resist cancer invasion, we must block the factor(s) that plays a pivotal 
role in cancer progression. Our decision to target CXCL12 stemmed from numerous studies 
demonstrating the fundamental role that CXCL12 plays in up-regulating cancer pathways 
and recruiting immunosuppressive cell types to the tumor microenvironment. CXCR4 is the 
most widely expressed chemokine receptor, with high expression in many different 
hematological and solid cancers (16). High expression of CXCR4 is associated with high 
rates of liver metastasis and poor survival (4). CXCR4 is activated by the exclusive binding 
of its ligand CXCL12. CXCL12 activates essential signaling pathways, including epidermal 
growth factor receptor, mitogen-activated protein kinase (MAPK), phosphoinositide 3-
kinase/protein kinase B (PI3K/AKT), WNT, and nuclear factor kB (NF-kB), which mediate 
cancer cell proliferation, growth, migration, invasion, and survival (17). Recent studies 
suggest that the stimulation of tumor cell proliferation via CXCL12 is MAPK-dependent 
(18, 19). This CXCL12 stimulation can further be categorized as an autocrine mechanism, in 
which CXCL12 activates RAS and MAPK, allowing for the production of various 
transcription factors including c-MYC. These transcription factors further up-regulate the 
expression of CXCR4, resulting in enhanced sensitivity to CXCL12 (17, 20). Another study 
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found that inhibition of CXCL12/CXCR4 signaling decreased pancreatic cancer 
proliferation and progression in vitro via inactivation of the canonical WNT pathway (21). 
In addition, CXCL12 influences tumor growth through activation of the PI3K/AKT pathway 
(18, 19). The ability of CXCL12 to drive tumor cell survival was also established in a study 
suggesting that CXCL12 expression activates NF-kB and suppresses apoptotic signaling 
(22).
The progression of cancer from the primary lesion to distant metastatic lesions is the product 
of a highly organized and tissue-selective process. One such mechanism involves CXCL12 
directing metastasis to select tissues through the establishment of a chemokine gradient. The 
CXCL12 chemokine can interact with glycosaminoglycan on the surface of endothelial cells 
and in the extracellular matrix to produce a concentration gradient. This chemokine gradient 
directs leukocyte and tumor cell migration toward a select tissue. In addition, CXCR4 is 
expressed in CRC progenitor cells and plays a role in maintaining these cancer stem-like 
cells (5, 6). Human breast cancer is another such example, where CXCR4 is highly 
expressed and stimulated by CXCL12 in both primary and metastatic lesions. CXCL12 is 
highly expressed in organs to which breast cancer disseminates, such as lung, bone, and 
liver. In vivo studies have demonstrated that neutralization of the CXCL12/CXCR4 axis 
impairs metastasis resulting from chemotactic and invasive responses in breast cancer 
models (23). CXCR4 is also involved in the metastasis of prostate cancer cells to the bone 
marrow, where a higher population of CXCR4+ cells are found at the metastatic sites 
compared to the primary tumor (24, 25).
The research presented in this report demonstrates the therapeutic benefits of inhibiting 
CXCL12 in the liver of aggressive liver metastasis cancer models. Directly disrupting the 
activation of CXCR4+ cancer cells by inhibiting CXCL12 in an immunodeficient CRC liver 
metastasis mouse model reduced the establishment of liver metastasis. Furthermore, in 
immunocompetent colorectal and breast cancer liver metastasis mouse models, we 
demonstrated that disrupting the CXCL12/CXCR4 pathway also plays a crucial role in 
inhibiting the tumor immunosuppresive microenvironment. CXCL12/CXCR4 plays a critical 
role in the recruitment of leukocytes, plasmacytoid dendritic cells, MDSCs, and neutrophils 
to sites of inflammation (13). Studies have suggested that increasing amounts of CXCL12 
are produced by the HSCs during liver inflammation. This local increase in CXCL12 
production drives recruitment and activation of tumor and immune cells to the 
microenvironment. These infiltrating cells provide an additional source of CXCL12 at the 
inflammation site (metastatic lesion), which further activates tumor growth, survival, 
angiogenesis, and metastasis. Our results suggest that delivery of a CXCL12 trap to the liver 
not only disrupts cancer activation by inhibiting CXCL12/CXCR4 interaction but also 
inhibits the recruitment of CXCR4+ immunosuppressive cells such as MDSCs and Tregs. 
Therefore, we hypothesize that our therapy works by two major pathways, directly inhibiting 
the CXCL12/CXCR4 stimulation of cancer cells and reducing the recruitment of CXCR4+ 
immunosuppresive cells to allow for increased cancer-specific CD8+ T cell killing. The local 
(liver) and transient (4 days) expression of the engineered CXCL12 trap has the potential to 
influence the immune response and the cancer biology driving the establishment of 
metastasis. These findings may provide a basis for future strategies for targeting metastatic 
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lesions, in which the co-delivery of genes expressing traps against a chemokine such as 
CXCL12 and an immune checkpoint protein could work in a synergistic manner.
Clinically, it has been suggested that the number of CXCR4+ CRC cells in a patient can be 
used as a biomarker to determine which patients may have a more aggressive and higher rate 
of liver metastasis (4, 7). Therefore, patients with a large population of CXCR4+ cells may 
be optimal candidates for a treatment targeting the CXCL12/CXCR4 axis in conjunction 
with other therapies. However, it is also clear that endogenous CXCL12 plays a crucial role 
in leukocyte recruitment, and therefore, systemic administration of free anti-CXCL12 
proteins would elicit serious toxicities. We demonstrate that these toxicities can be avoided 
through the local and transient delivery of LCP gene vector. This pTrap LCP vector enabled 
us to greatly decrease the occurrence of colorectal liver metastasis (80%) and drastically 
decrease the tumor burden found within the liver (10-fold). Increased concentrations of the 
CXCL12 trap and decreased concentrations of free CXCL12 protein were found in the liver 
in a dose-dependent manner. This approach also reduced the recruitment of immune 
suppressor cells (MDSCs and Tregs), demonstrating a biologically specific effect of pTrap 
LCP treatment. The insufficient target specificity of most small-molecule and protein 
therapies as well as the toxicity concerns that revolve around the use of viral vectors for gene 
therapy have limited the clinical applications. Furthermore, many nonviral vectors for gene 
therapy have fallen short because of extracellular and intracellular barriers in vivo. However, 
the delivery of pDNA in an LCP vector shows no signs of off-target effects, with minimal to 
no adverse immune response after repeated injections. The ability to have transient 
expression of this small CXCL12 trap (~28.6 kDa) (fig. S7) lasting up to about 4 days would 
allow clinicians to tightly control and monitor the extent and time of expression to limit 
undesired immune responses and still achieve therapeutic efficacy. Moreover, the in vivo 
pDNA dose used in our study (0.5 mg/kg per injection) is substantially lower than doses 
previously shown to have in vivo expression (26). In the past, therapeutic pDNA has only 
been successfully delivered to the liver via viral vectors or through invasive hydrodynamic 
injection (27). Therefore, a nonviral vector capable of delivering a therapeutic gene, such as 
the CXCL12 trap, should have high translatability to the clinic.
Although this LCP platform and many other nonviral vectors have aimed to improve pDNA 
expression in vivo, the expression of nonviral vectors still falls short compared to viral gene 
delivery systems. This gap can only be lessened through innovative technologies aimed at 
improving the limitations in nuclear localization and release of pDNA. Furthermore, the 
preclinical animal models used to test a vector’s therapeutic potential need to more 
accurately mirror the clinical profile. The use of cell line–based models and nonorthotopic 
implantation introduce artifacts that limit our capacity to measure the nonviral vector’s 
ability to treat clinical disease. These limitations will need to be addressed to bring about 
successful translation of these gene delivery vectors to the clinic.
MATERIALS AND METHODS
For detailed Materials and Methods, please see the Supplementary Materials.
Goodwin et al. Page 11
Sci Transl Med. Author manuscript; available in PMC 2017 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Binding affinity and effect of engineered CXCL12 trap protein on in vitro cellular 
migration and invasion
(A) Binding affinity between CXCL12 trap and CXCL12 measured by BLI, where CXCL12 
was immobilized on the AR2G biosensor and the binding kinetics were measured against no 
CXCL12 trap (0 nM) and increasing concentrations of CXCL12 trap (125, 250, and 500 
nM) to determine the kon and koff rates depicted by the tracing of signal intensities versus 
time. The Kd was calculated to be 4.1 ± 0.4 nM after determining the on and off rate 
depicted. RU, resonance units. (B) The Chemotaxis Migration Assay Kit (EMD Millipore) 
with a pore size of 8 μm was used to investigate inhibition of cellular migration. We 
analyzed CT-26(FL3) cell migration toward a concentration gradient of CXCL12 (10 nM) in 
the presence of CXCL12 trap (60, 120, 240, or 360 nM). A positive control CXCL12 
antibody (6, 12, or 24 nM) was also used. The engineered CXCL12 trap was found to have 
one-half maximal inhibition (ND50) against biologically active CXCL12 (10 nM) at a 
concentration of 120 nM. (C) Invasion Assay Kit (EMD Millipore) with a pore size of 8 μm 
and ECMatrix were used to analyze the increase in CT-26(FL3) cell invasion toward a 
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concentration gradient of CXCL12 (10 nM) in the presence or absence of CXCL12 trap (120 
or 240 nM) or control CXCL12 antibody (24 nM). Data are means ± SD, calculated from 
samples performed in triplicate and as a percentage of untreated (no CXCL12 or treatment 
protein) control. Cell migration and invasion were determined through cell collection, lysis, 
and quantification by luciferase bio-luminescent analysis. Statistical significance is indicated 
in graph compared to the control containing CXCL12 (10 nM) in the feeder (lower) plate 
without CXCL12 trap or antibody. N.S., not significant.
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Fig. 2. Transient liver-specific expression of pGFP and engineered pTrap
(A) Microscopy analysis of GFP expression in major LCP-accumulating organs. The liver 
sections demonstrate transient expression for at least 4 days after the final injection (10 mg 
every other day × 3). Scale bar, 250 μm. Data are means ± SD, calculated from at least 
triplicated samples and reported as fluorescence intensity quantified by ImageJ software. 
N.D., under detection limit; P values represent significance of the difference from untreated 
sample. Scale bar, 250 μm. DAPI, 4′,6-diamidino-2-phenylindole; IV, intravenous. (B) 
His(6×)-tag ELISA and Western blot analysis were conducted to determine the organ 
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distribution/expression of the pTrap in all major LCP-accumulating organs and serum. Doses 
were escalated from 2.0 to 10.0 and 20.0 mg of pDNA administered via tail vein. (C) 
Western blot analysis of organs shows CXCL12 trap expression using His(6×) monoclonal 
antibody. The expression is transient and only lasts for 4 to 8 days after the final injection 
(10 mg every other day × 3). Total protein concentrations were determined by bicinchoninic 
acid assay, BCA, and 50 mg of total protein was loaded per well/lane. Trap protein was 
detected at 28.6 kDa, as confirmed by a protein standard ladder, consistent with the 
theoretical value. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a 
loading control, except in the serum samples, where GAPDH is not present. Data are means 
± SD, calculated from samples run in triplicate and shown as a fold increase compared to 
untreated control. The P values of groups compared to corresponding untreated control are 
displayed in graphs.
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Fig. 3. Biological trapping of endogenous CXCL12 and immune cell recruitment
(A) Endogenous CXCL12 expression in paraffin-embedded sections of liver tissues from 
BALB/c mouse models of CRC sacrificed 10 days after the final treatment injection and 
control healthy livers [healthy (no CRC)]. Immunofluorescence stain for CXCL12 (red), 
along with DAPI nuclear stain (blue). Five groups were studied, including healthy (no CRC), 
untreated (PBS), pGFP LCP control [10 mg every other day (QOD) × 3], pTrap LCP (10 
mg), and pTrap LCP (10 mg every other day × 3). All data are means ± SD, calculated from 
samples run in triplicate and reported as fluorescence intensity. The P values of individual 
groups compared to corresponding untreated control are displayed in graphs. (B) Additional 
sections were stained to determine the recruitment of immune cells to the liver, including 
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immunosuppressive anti-inflammatory MDSCs [CDllb+ (green)/GR1+ (red)] and Tregs 
[CD4+ (green)/Foxp3+ (red)] as well as the CD8+ T cell population (green). Four groups 
were studied, including healthy (no CRC), untreated (tumor), untreated (stroma), and pTrap 
LCP (10 mg every other day × 3). Trichrome staining is also shown to distinguish normal 
and diseased liver. White arrows indicate metastatic lesions. All data are means ± SD, 
calculated from samples run in triplicate and reported as fluorescence intensity relative to 
untreated control. The P values of individual groups compared to corresponding untreated 
control are displayed in graphs. Scale bars, 250 μm.
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Fig. 4. Decreased incidence of liver metastasis after pTrap LCP treatment
(A) Mice were inoculated with 2 × 106 CT-26(FL3) RFP/Luc cells into the cecum wall. 
Treatment schedule is shown above. Treatment, 10 mg (0.5 mg/kg) of pDNA, was 
administered intravenously through the tail vein on days 10, 12, and 14. Groups included 
PBS (untreated; n = 7) and pGFP LCP (10 mg every other day × 3; n = 6), as well as pTrap 
LCP (10 mg every other day × 3; n = 7). Progression of overall tumor mass was followed by 
administration of 200 of ml luciferin (10 mg/ml) intraperitoneally. Luciferase 
bioluminescence imaging was recorded 10 min after administration of luciferin. Whole 
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mouse and liver tumor burden were recorded. All data are means ± SD and reported as 
bioluminescent intensity. The P values of individual groups compared to corresponding 
untreated control are displayed in graph. (B) Total organ tumor burden of untreated (n = 3) 
and therapeutic pTrap LCP (n = 4) groups. Quantification of tumor burden in organs was 
performed with IVIS/Kodak software. All data are means ± SD and reported as 
bioluminescent intensity. The P values of individual groups compared to corresponding 
untreated control are displayed in graph. (C) Paraffin-embedded liver sections were stained 
with trichrome. Large tumor burden (indicated by black arrows) and cirrhosis/fibrosis (blue 
stain, collagen) are clearly seen in the PBS (untreated) and pGFP LCP treatment groups. The 
pTrap LCP– treated livers have normal healthy liver morphology and no detectable 
metastatic burden. Scale bars, 250 μm. Collagen quantification in liver section was recorded. 
All data are means ± SD. The P values of individual groups compared to corresponding 
untreated control are displayed in graph.
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Fig. 5. Decreased incidence of liver metastasis and enhanced T cell killing after pTrap LCP 
therapy
Mice were inoculated with 2 × 106 CT-26(FL3) RFP/Luc cells into the cecum wall. 
Treatment, 10 mg (0.5 mg/kg) of pDNA, was administered intravenously through the tail 
vein on days 10, 12, and 14. Groups included PBS (untreated; n = 5) and pTrap LCP (10 mg 
every other day × 3; n = 5) with either anti-Lyt2.2 or isotype IgG control administrated on 
days 8 and 10 (400 mg, 20 mg/kg) intraperitoneally (IP). Inoculation and treatment 
schedule/dose and liver tumor mass on day 21 are shown above. Mice were administered 
200 ml of luciferin (10 mg/ml) intraperitoneally. After 5 min, mice were euthanized, and 
livers were extracted, rinsed in PBS, and placed in a solution of luciferin (1 mg/ml). The 
bioluminescence images were recorded using IVIS Kinetic with Kodak camera. 
Quantification of tumor burden in the liver was performed with IVIS/Kodak software. Data 
were expressed as log-transformed mean, normalized ± SE. The P values of individual 
groups compared to corresponding untreated control are displayed in graph.
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Fig. 6. Decreased incidence of 4T1 liver metastasis and increased survival after pTrap LCP 
treatment
(A) Inoculation and treatment schedule and doses, as well as bioluminescent signal detection 
and tumor burden quantification 7 days after inoculation. Treatment groups included PBS 
(untreated; n = 5), pGFP LCP/anti-CD8 (n = 5), pTrap LCP/anti-CD8 (n = 5), and pTrap 
LCP/isotype IgG (n = 5). Data were expressed as log-transformed mean, normalized ± SE. 
The P values of individual groups compared to corresponding untreated control are 
displayed in graph. (B) Flow cytometry analysis of tumor burden and quantification on day 
10 (n = 3 per group). Gating consists of GFP+ tumor cells (P3) versus non-GFP+ cells (P4). 
Data were expressed as mean, normalized ± SD. The P values of individual groups 
compared to corresponding untreated control are displayed in graph. FITC, fluorescein 
isothiocyanate. (C) Kaplan-Meier survival curve including all four treatment groups (n = 5 
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per group). Survival was determined by evaluating mouse weight, activity, and quality of 
life. The P values of individual groups compared to corresponding untreated control are 
displayed in graph.
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Fig. 7. Comparison of therapeutic strategies for reducing incidence of CRC (HT-29) liver 
metastasis
(A) The timeline at the top shows the inoculation and treatment schedule and dosing for the 
HT-29. Treatments were administered intravenously through the tail vein every other day on 
days 0 to 16. Treatment groups included PBS (untreated; n = 5), pGFP LCP [10 mg (0.5 
mg/kg) of pDNA; n = 5], pTrap LCP [10 mg (0.5 mg/kg) of pDNA; n = 5], free CXCL12 
trap protein [10 mg (0.5 mg/kg) of protein; n = 5], and AMD3100 (100 mg, 5.0 mg/kg; n = 
5). (B) Tumor burden analysis and quantification on day 36 (n = 5 per group). Liver 
metastasis burden was quantified by resection and weighing of tumor nodules (in mg). The 
image shows a representative liver from each treatment group with metastatic burden shown, 
and white arrows indicate metastatic lesions. Survival was determined by evaluating mouse 
weight, activity, and quality of life. Data were expressed as individual data points with 
means ± SD. The P values of individual groups compared to corresponding untreated control 
are displayed in graph.
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Fig. 8. Toxicological analysis
(A) ALT, AST, creatinine, and BUN measurements and blood leukocyte cell counts 24 hours 
after the final treatment with PBS (untreated), 10 mg of pGFP LCP (every other day × 3), 10 
mg of pTrap LCP (every other day × 3), or 20 mg of free CXCL12 trap protein (every other 
day × 3), in which mice were sacrificed on days 1, 7, and 14 after the final administration. 
All data are means ± SD from samples run in triplicate. The P values of individual groups 
compared to corresponding untreated control are displayed in graph. (B) Trichrome 
histology sections of different organs 24 hours after the final treatment with PBS (untreated), 
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10 mg of pGFP LCP (every other day × 3), 10 mg of pTrap LCP (every other day × 3), or 20 
mg of free CXCL12 trap protein (every other day × 3), in which mice were sacrificed on 
days 1, 7, and 14 after the final administration. All trichrome histology sections show no 
toxicity in any major organ including heart, lung, spleen, kidney, and liver. Scale bar, 100 
μm.
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